Refining Approaches to Reach Treatment Goals in mRCC

Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.

Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.